{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:50:28Z","timestamp":1790344228643,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tcm.2025.08.004","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T23:34:34Z","timestamp":1754955274000},"page":"76-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of randomized controlled studies comparing ablation with antiarrhythmic drugs"],"prefix":"10.1016","volume":"36","author":[{"given":"Nawar","family":"Alhourani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ellermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Wolfes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-8503","authenticated-orcid":false,"given":"Lars","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9989","key":"10.1016\/j.tcm.2025.08.004_bib0001","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.tcm.2025.08.004_bib0002","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"issue":"40","key":"10.1016\/j.tcm.2025.08.004_bib0003","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1093\/eurheartj\/ehac471","article-title":"Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial","volume":"43","author":"Eckardt","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.tcm.2025.08.004_bib0004","first-page":"836","article-title":"Comparison of the latest ESC, ACC\/AHA\/ACCP\/HRS, and CCS guidelines on the management of atrial fibrillation","volume":"11","author":"Wolfes","year":"2025","journal-title":"JACC: Clin Electrophysiol"},{"issue":"14","key":"10.1016\/j.tcm.2025.08.004_bib0005","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jama.2024.17921","article-title":"Pulmonary vein isolation vs sham intervention in symptomatic atrial fibrillation","volume":"332","author":"Dulai","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.tcm.2025.08.004_bib0006","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2029554","article-title":"Cryoballoon ablation as initial therapy for atrial fibrillation","volume":"384","author":"Wazni","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.tcm.2025.08.004_bib0007","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/europace\/euab029","article-title":"Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation","volume":"23","author":"Kuniss","year":"2021","journal-title":"Europace"},{"issue":"4","key":"10.1016\/j.tcm.2025.08.004_bib0008","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation","volume":"384","author":"Andrade","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.tcm.2025.08.004_bib0009","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jama.2014.467","article-title":"Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2)","volume":"311","author":"Morillo","year":"2014","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.tcm.2025.08.004_bib0010","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1113566","article-title":"Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation","volume":"367","author":"Cosedis Nielsen","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.tcm.2025.08.004_bib0011","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1001\/jama.293.21.2634","article-title":"Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation","volume":"293","author":"Wazni","year":"2005","journal-title":"JAMA"},{"issue":"36","key":"10.1016\/j.tcm.2025.08.004_bib0012","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.tcm.2025.08.004_bib0013","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/europace\/eux373","volume":"20","author":"Dan","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.tcm.2025.08.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euaf076","article-title":"Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the european heart rhythm association of the ESC","author":"Merino","year":"2025","journal-title":"Europace"},{"issue":"46","key":"10.1016\/j.tcm.2025.08.004_bib0015","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1093\/eurheartj\/ehz782","article-title":"Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation","volume":"40","author":"Willems","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2025.08.004_bib0016","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.tcm.2023.04.001","article-title":"Benefits of early rhythm control of atrial fibrillation","volume":"34","author":"Eckardt","year":"2024","journal-title":"Trend Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.tcm.2025.08.004_bib0017","doi-asserted-by":"crossref","first-page":"euae121","DOI":"10.1093\/europace\/euae121","article-title":"Safety and efficacy of long-term Sodium Channel Blocker therapy for Early Rhythm Control: The EAST-AFNET 4 trial","volume":"26","author":"Rillig","year":"2024","journal-title":"Europace"},{"issue":"9","key":"10.1016\/j.tcm.2025.08.004_bib0018","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jacc.2021.06.038","article-title":"Cryoballoon ablation as initial treatment for atrial fibrillation: JACC state-of-the-art review","volume":"78","author":"Andrade","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2025.08.004_bib0019","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.amjcard.2023.11.052","article-title":"Ablation versus antiarrhythmic drugs as first-line therapy for treatment-naive atrial fibrillation: systematic review and meta-analysis","volume":"213","author":"Ullah","year":"2023","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.tcm.2025.08.004_bib0020","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/01.CIR.92.6.1517","article-title":"Efficacy and safety of d -sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy","volume":"92","author":"Hohnloser","year":"1995","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.tcm.2025.08.004_bib0021","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0008-6363(98)00043-1","article-title":"Experimental models of torsade de pointes","volume":"39","author":"Eckardt","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.tcm.2025.08.004_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.581837","article-title":"Revisiting antiarrhythmic drug therapy for atrial fibrillation: reviewing lessons learned and redefining therapeutic paradigms","volume":"11","author":"Geng","year":"2020","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.tcm.2025.08.004_bib0023","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/eurjhf\/hfr107","article-title":"A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure","volume":"13","author":"Frommeyer","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.tcm.2025.08.004_bib0024","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/europace\/euq450","article-title":"Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation","volume":"13","author":"Freemantle","year":"2011","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.tcm.2025.08.004_bib0025","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1074248419887710","article-title":"Multicenter Analysis of Dosing Protocols for Sotalol Initiation","volume":"25","author":"Biswas","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.tcm.2025.08.004_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/1753944720926824","article-title":"Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12\u2009months: a retrospective study","volume":"14","author":"Muzzey","year":"2020","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.tcm.2025.08.004_bib0027","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/europace\/euq382","article-title":"Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation","volume":"13","author":"Aliot","year":"2011","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.tcm.2025.08.004_bib0028","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1253\/circj.71.294","volume":"71","author":"Atarashi","year":"2007","journal-title":"Circ J"},{"issue":"7","key":"10.1016\/j.tcm.2025.08.004_bib0029","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/europace\/eup119","article-title":"Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study","volume":"11","author":"Andersen","year":"2009","journal-title":"Europace"},{"issue":"7","key":"10.1016\/j.tcm.2025.08.004_bib0030","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjcard.2019.12.041","article-title":"Use of Flecainide for the Treatment of Atrial Fibrillation","volume":"125","author":"Echt","year":"2020","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.tcm.2025.08.004_bib0031","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1211\/0022357055128","article-title":"Assessment of serum flecainide trough levels in patients with tachyarrhythmia","volume":"57","author":"Homma","year":"2005","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10.1016\/j.tcm.2025.08.004_bib0032","article-title":"Open-label, multicenter study of flecainide acetate oral inhalation solution for acute conversion of recent-onset, symptomatic atrial fibrillation to sinus rhythm","volume":"15","author":"Crijns","year":"2022","journal-title":"Circulat: Arrhythm Electrophysiol"},{"key":"10.1016\/j.tcm.2025.08.004_bib0033","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijcard.2018.09.029","article-title":"Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low dose intratracheal or intravenous administration","volume":"274","author":"Marum","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2025.08.004_bib0034","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-025-02637-0","article-title":"Safety and efficacy of amiodarone and dronedarone for early rhythm control in EAST-AFNET 4","author":"Rottner","year":"2025","journal-title":"Clin Res Cardiol"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825001082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825001082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:32:26Z","timestamp":1770885146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173825001082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1050173825001082"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2025.08.004","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of randomized controlled studies comparing ablation with antiarrhythmic drugs","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2025.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}